Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
13
BOLT Quote, Financials, Valuation and Earnings
Last price:
$4.46
Seasonality move
:
-26.44%
Day range:
$4.29 - $4.72
52-week range:
$3.91 - $9.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.05x
P/B ratio:
0.31x
Volume:
15.6K
Avg. volume:
19.1K
1-year change:
-46.51%
Market cap:
$8.1M
Revenue:
$7.7M
EPS (TTM):
-$12.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$1.5M | -$3.60 | 22.75% | -33.72% | $29.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$952.5M | $1.10 | 3.04% | 4.71% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$1.27 | -- | -60.16% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$4.29 | $29.00 | $8.1M | -- | $0.00 | 0% | 6.05x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
IMNN
Imunon, Inc.
|
$3.22 | $21.50 | $7.4M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
46.42% | 0.699 | 218.75% | 3.28x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 7.808 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
|
$2.2M | -$5.6M | -51.81% | -82.84% | -224.2% | -$7.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
Bolt Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns BOLT or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -265.24% compared to Bolt Biotherapeutics, Inc.'s net margin of 96.33%. Bolt Biotherapeutics, Inc.'s return on equity of -82.84% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.89.8% -$3.84 $49.5M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About BOLT or ACAD?
Bolt Biotherapeutics, Inc. has a consensus price target of $29.00, signalling upside risk potential of 575.99%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 1 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is BOLT or ACAD More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.863, which suggesting that the stock is 13.693% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock BOLT or ACAD?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or ACAD?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Bolt Biotherapeutics, Inc.'s net income of -$6.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 6.05x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.6.05x -- $2.5M -$6.6M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns BOLT or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -265.24% compared to Bolt Biotherapeutics, Inc.'s net margin of 16.99%. Bolt Biotherapeutics, Inc.'s return on equity of -82.84% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.89.8% -$3.84 $49.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About BOLT or ALNY?
Bolt Biotherapeutics, Inc. has a consensus price target of $29.00, signalling upside risk potential of 575.99%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is BOLT or ALNY More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.863, which suggesting that the stock is 13.693% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock BOLT or ALNY?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or ALNY?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Bolt Biotherapeutics, Inc.'s net income of -$6.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 6.05x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.6.05x -- $2.5M -$6.6M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns BOLT or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -265.24% compared to Bolt Biotherapeutics, Inc.'s net margin of -5.2%. Bolt Biotherapeutics, Inc.'s return on equity of -82.84% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.89.8% -$3.84 $49.5M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About BOLT or BMRN?
Bolt Biotherapeutics, Inc. has a consensus price target of $29.00, signalling upside risk potential of 575.99%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 1 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is BOLT or BMRN More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.863, which suggesting that the stock is 13.693% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock BOLT or BMRN?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or BMRN?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.5M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Bolt Biotherapeutics, Inc.'s net income of -$6.6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 6.05x versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.6.05x -- $2.5M -$6.6M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns BOLT or IMNN?
Imunon, Inc. has a net margin of -265.24% compared to Bolt Biotherapeutics, Inc.'s net margin of --. Bolt Biotherapeutics, Inc.'s return on equity of -82.84% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.89.8% -$3.84 $49.5M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About BOLT or IMNN?
Bolt Biotherapeutics, Inc. has a consensus price target of $29.00, signalling upside risk potential of 575.99%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than Imunon, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 1 0 IMNNImunon, Inc.3 1 0 -
Is BOLT or IMNN More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.863, which suggesting that the stock is 13.693% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.653%.
-
Which is a Better Dividend Stock BOLT or IMNN?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or IMNN?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.5M, which are larger than Imunon, Inc. quarterly revenues of --. Bolt Biotherapeutics, Inc.'s net income of -$6.6M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 6.05x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.6.05x -- $2.5M -$6.6M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns BOLT or SVRA?
Savara, Inc. has a net margin of -265.24% compared to Bolt Biotherapeutics, Inc.'s net margin of --. Bolt Biotherapeutics, Inc.'s return on equity of -82.84% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital BOLTBolt Biotherapeutics, Inc.89.8% -$3.84 $49.5M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About BOLT or SVRA?
Bolt Biotherapeutics, Inc. has a consensus price target of $29.00, signalling upside risk potential of 575.99%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Bolt Biotherapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Bolt Biotherapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BOLTBolt Biotherapeutics, Inc.2 1 0 SVRASavara, Inc.6 0 0 -
Is BOLT or SVRA More Risky?
Bolt Biotherapeutics, Inc. has a beta of 0.863, which suggesting that the stock is 13.693% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock BOLT or SVRA?
Bolt Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOLT or SVRA?
Bolt Biotherapeutics, Inc. quarterly revenues are $2.5M, which are larger than Savara, Inc. quarterly revenues of --. Bolt Biotherapeutics, Inc.'s net income of -$6.6M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Bolt Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics, Inc. is 6.05x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOLTBolt Biotherapeutics, Inc.6.05x -- $2.5M -$6.6M SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
